Bioventus cuts 2026 revenue view to $590m-$595m

Bioventus cut its 2026 revenue outlook to $590 million to $595 million after Q3 revenue rose 3% to $142 million, according to Seeking Alpha earnings-call material published Nov. 3.

Bioventus had reaffirmed a $600 million to $610 million revenue range in Q2, while keeping full-year adjusted earnings per share guidance at $0.75 to $0.79 per diluted share in Q3.

Chief Financial Officer Mark Singleton said adjusted EBITDA was $28 million in Q3, with a 20% adjusted EBITDA margin that widened 70 basis points from the prior-year period. Adjusted earnings were $0.17 per diluted share, and cash flow from operations was $21 million.

"With lower revenue expectations, primarily in BGS, we now expect 2026 revenue of $590 million to $595 million," Singleton said on the call, referring to bone graft substitutes, products used in surgical procedures to support bone healing. He said the company was reaffirming full-year adjusted EPS guidance.

Pain Treatments was the strongest reported segment, with revenue of $71 million in Q3 and 6% growth, Chief Executive Robert Claypoole said. Surgical Solutions revenue was $51 million, Restorative Therapies revenue was $21 million and international revenue was $18 million, according to Singleton.

Management attributed the lower revenue view mainly to softness in bone graft substitutes. Singleton cited modest weakness in spine procedures, temporary delays in adding new distributors and competitive dynamics in the synthetic market, while saying Bioventus made changes late in Q3 and saw better trends at the start of Q4.

Claypoole said the company’s strategic review remains active but gave no timetable or detail. "With the assistance of our advisers, we continue to evaluate a range of strategic options for the company," he said, adding that management would not answer questions about the review.

Bioventus also pointed to growth initiatives in platelet-rich plasma, or PRP, and peripheral nerve stimulation, or PNS. Claypoole said Q3 revenue from PRP disposable kits exceeded revenue from capital placements, and that Bioventus had secured exclusive rights from APEX Biologix to offer its PRP solution in sports medicine accounts.

For PNS, Claypoole said trial-to-permanent conversion rates were ahead of plan, the time from trial to permanent implant placement had shortened and the number of trained physicians increased by more than 50% from the prior quarter. He declined to issue 2027 guidance but said management expects the business to scale to more than $100 million in coming years.

The balance sheet remained a focus. Singleton said Bioventus ended Q3 with $31 million in cash and $230 million of outstanding debt, and reiterated that the company expects net leverage to fall below 1.5 times by year-end. Claypoole said $21 million of operating cash flow funded $19 million of debt repayment in the quarter, reducing net debt to below $200 million.

Fourth-quarter checks

For Q4 2026, management expects mid-single-digit revenue growth and sequential acceleration in revenue and earnings, according to Singleton and Claypoole.

By year-end 2026, Bioventus expects its net leverage ratio to be below 1.5 times, according to Singleton. The company ended Q3 with $31 million of cash on hand and $230 million of outstanding debt.

For full-year 2026, the updated revenue range is $590 million to $595 million, while adjusted earnings per share guidance remains $0.75 to $0.79 per diluted share, according to Singleton.

Source: earnings-call insights, Seeking Alpha, Nov. 3